Molecular Partners AG
MOLN
Ранг среди акций
#19815
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Цена акции
$3.69
Рыночная капитализация
$141.31M
Изменение (1 день)
-7.00%
Изменение (1 год)
3.11%
Страна
CH
Торговля Molecular Partners AG (MOLN)
Категория
Healthcare
Коэффициент P/B для Molecular Partners AG (MOLN)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Molecular Partners AG, текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Molecular Partners AG с 2026 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| Недостаточно данных для указанных дат. | ||
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| 6.1824 | - |
NL
|
|
| - | - |
CH
|
